Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old

Inclusion Criteria

• •Male/Female children aged 5-11 years
• •Written informed consent obtained by parents/legal representative (according to local regulation) and by the minor (age and local regulation permitting).
• •children with stable asthma on regular treatment with ICS or using short-acting inhaled beta2-agonists as reliever to control asthma symptoms
• •Forced expiratory volume in one second (FEV1) \> 70% of predicted values (% pred) after withholding beta2-agonist treatment for a minimum of 4 h prior to each dose period.
• •6\. A cooperative attitude and ability to be trained about the proper use of pMDI with a spacer device and compliant to study procedures.